Introduction
Intrahepatic cholangiocarcinoma is the second most frequent type of primary liver cancer with an increasing global incidence during the past decades. Although hepatectomy is the curative method for early ICC, 5-year survival rate after resection wavers around 30-35% [1] . For those in the late stage that only receive cisplatinbased chemotherapy, the median overall survival is as low as 11.7 months [2] . The lack of commonly-accepted effective of medical care highlights the importance of understanding the ICC pathogenesis to develop new treatment strategies [3] .
Recently, genomic sequencing studies have taken insights into the genetic landscape of ICC [4] [5] [6] . The driver alterations identified in ICC may represent potential candidates for personalized targeted therapy. However, genomic alterations identified in most of these studies were obtained by single sampling in individual cases, and little is known about the spatial ITH or temporal clonal evolutionary processes in ICC. In fact, anti-tumor drug development may require not only an understanding of genetic alterations but also an apprehension of the clonal status of driver alterations and evolutionary processes. During tumor progression, accumulating somatic mutations bestow a selective advantage on subclonal expansion, through which the fittest subclone will dominate. In turn, the presence of subclonal mutations may affect the efficacy of the targeted therapy. For example, in BRAFV600-mutant melanoma, the subclonal heterogeneity of PI3K-PTEN-AKT signaling are involved in the resistance to BRAF inhibitors [7] . Therefore, therapeutics targeting clonal somatic events or combination of multiple target sites seems to be more effective.
Studies adopting multiregional WES have unveiled the complex ITH and evolution pattern in several types of cancer, including prostate cancer, hepatocellular carcinoma and non-small cell lung cancer [8] [9] [10] [11] . Since ICC contains a large proportion of nontumor components [12] , sequencing tumor sample directly may be confounded by low tumor purity, resulting in unexpected impacts on the accuracy of mutation landscape and clonal structure. As a countermeasure, PDPCs obtained by single sampling were developed for their high purity and cell population representativeness [13] .
Previous study on hepatocellular carcinoma and lung cancer have shown that PDPCs can be an accurate assessment of intratumor genetic heterogeneity and represent a potential powerful tool for drug screening [13] [14] [15] .
To reconstruct the genome history and evaluate how clonal structure can affect therapeutic responses in ICC, we performed multiregional WES of 6 ICC tumors containing a total of 69 related PDPCs that represented the broad intratumor mutational spectrum. The multiregional cell culture model derived from geographical sampling allowed us to study mutation frequencies, observe clonal evolution, and correlate evolution process with therapy development for ICC.
Method:

Patients and Sample Collection
Samples were collected from patients diagnosed with ICC who underwent curative resection without any adjuvant therapy before. All 6 patients were from Zhongshan Hospital of Fudan University. Patents' clinicopathologic information was presented in Supplementary Table 1 . After resection, characteristic spatially separated regions of each primary tumor were collected as previously described [15] . Major part of each region was subjected to primary culture, and minor part was sent to H&E staining.
Details of the establishment of PDPCs are described in the Supplementary Material.
The study was approved by the Research Ethics Committee of Zhongshan Hospital, and written informed consent was obtained from each patient.
WES,
Sanger validation, Fluorescent in situ hybridization, Immunohistochemistry, Cell proliferation assays, Genome-wide analysis of mutation calling, copy number alteration (CNA) and phylogenetic tree construction, and Statistical analysis.
see Supplementary Materials and Methods sections.
RESULTS
Establishment of multiregional patient-derived primary cancer cells from ICC
To illustrate ITH in ICC, fresh tissues were collected from 69 spatially distinct tumor regions (range, 7-16 per case) in 6 cases, who received curative resection (Supplementary Table 1 ). In particular, ICC1239P and ICC1239R were resected from the same patient, the latter of which was a recurrent lesion after 7 months of primary resection. Each sample was subjected to low-passage primary culture to generate PDPCs, followed by STR typing identification and WES (Graphical abstract). WES achieved a mean coverage of 100X on those 69 low-passage PDPCs and matched peripheral blood samples, as well as 300X on the corresponding tumor tissues (Supplementary Table 2 ).
As the low-passage primary culture would filter out most of the non-proliferative stromal components, the average purity of PDPCs finally achieved 94.4%(range, 67%-98% ), compared to 40%(range, 20%-54%) in the tumor tissues(Supplementary Figure 1A) . Thus, the high purity of PDPCs could minimize the confounding effect of non-tumor components on genomic analysis and was more conducive to build a model close to the real clonal structure [16] . Moreover, in each patient, the number of mutations detected in multiple PDPCs was significantly higher than that in its corresponding tissue (median, 832 vs 312) , while the mutations detected in the tissue with 300X sequencing depth was higher than those detected in any single PDPC with 100X depth (Supplementary Figure 1B) , indicating that both multi-regional sampling and higher sequencing depth could improve the efficiency of mutation detection. In addition, consistent with previous studies [13, 15] , there existed a similar mutation spectrum and mutation types between PDPCs and corresponding tissues.
Altogether, multi-regional PDPCs could cover the whole mutation landscape and clonal structure more efficiently.
Spatial intratumor heterogeneity and clonal status of SNV
We identified a total of 1,596 non-silent mutations, including 1,312 missenses, 85 nonsenses, 25 splice-site variants and 174 insertions or deletions in those 69 PDPCs.
Sanger validation of 1,331 randomly selected non-silent somatic mutations showed a high true discovery rate (94.4%) (Supplementary Table 4 ). Median number of nonsilent mutations was 93 in each PDPCs and regions from same patients had similar numbers of mutations ( Figure 1A , Supplementary Figure 2 and Supplementary Table   3 ). We found a high degree of spatial ITH in ICC. The median ITH index (Supplementary Method) is 60.3% (range 45.6%-71.6%), which is substantially higher than other cancers, such as esophageal adenocarcinoma (25%), non-small cell lung cancer (30%) and hepatocellular carcinoma (39%) [9, 15, 17] . In addition, we found that the genetic variability increased linearly with the number of sampling regions [18] , showing that more regions were needed to accurately estimate the ITH level ( Figure 1B ).
For each individual region, we calculated the cancer cell fraction (CCF) and classified the mutations as clonal or subclonal using Pyclone [19] . Notably, almost a half of mutations (median 42.8%, range 8.3% to 79.4%) were classified as subclonal,
implying that each individual region had high level of heterogeneity ( Figure 1C , Supplementary Figure 3 ). The proportion of subclonal mutations in the regions was higher than that of the cancers previously reported based on the TCGA data, such as bladder cancer (~18%), glioblastoma (~32%) and lung adenocarcinoma (~30%) [20] .
Remarkably, duo to great variations in some given variant allele frequency among regions, a number of variants detected as clonal within some tumor regions were subclonal or absent in other regions from the same patients, producing an "illusion" of clonal dominance [9, 21] , and these clonal illusion mutations were detected in nearly all regions ( Figure 1D ). For instance, in ICC892, a missense mutation in KDM3A (pAla776Val), a member of the Jumonji C-domain-containing histone demethylases involved in cisplatin-resistance in ovarian cancer and tamoxifen-resistance in breast cancer [22, 23] , was estimated to be clonal in regions R2, R3 and R8 but was subclonal in all other 8 regions ( Figure 1E ). In fact, without multiregional WES, nearly 8% of subclonal mutations would be misinterpreted as clonal events. This misinterpretation may have serious adverse influence on the targeted therapy if only one region was used for sequencing analysis.
Tumor evolution of ICC
We further used Pyclone to construct phylogenetic tree to elucidate the evolutionary trajectory of each patient [19] (Figure 2A ). On the phylogenetic trees, each cluster represented a node and the branch length was proportional to the mutation numbers in the corresponding cluster. In each patient, the trunk cluster consisted of clonal mutations and occured at early tumor stage. The trunk mutations formed the mutational profile of the founder population, representing optimal therapeutic targets.
All the 6 patients displayed clear evidence of branched evolution. About half of the tumor regions (35/69, 50.2%) carried subclones located in only a single branch of the phylogenetic tree, once again demonstrating a high level of heterogeneity. The trunk cluster of other cancer types often held the majority of the driver genes [9, 17, 24 ].
However, the driver genes in ICC were scattered along the phylogenetic tree, with only a minority located in the trunk. On average, trunk had only 4.3(15%) driver mutations and non-trunk had 24.7(85%) driver mutations. This indicated that the force to drive tumor diversity persisted along ICC evolution ( Figure 2B ). Considering the heterogeneity and the complex regulating network in ICC development [4, 5, 25] , we clustered non-truncal missense genes into multiple pathways using the KEGG database, which exhibited that cAMP signaling, Calcium signal, cGMP-PKG signal, Gap junction and ECM-receptor pathways may have a crucial role in ICC progression ( Figure 2C ). We also adapted a dN/dS model to quantify the selection pressure in the tree. Although these data were still limited, dN/dS~1 appeared to characterize somatic evolution in ICC, while the ratio in missense mutations was higher than that in nonsense mutations (Wilcoxon test, p=0.006) ( Supplementary Figure 4) .
The same patient could have different and seemingly functional redundant mutations in the same driver gene. This is consistent with the parallel evolution that the same genetic pathway within a tumor was independently destroyed in different tumor subpopulations [26] . For example, in ICC772, two separate subclonal lineages, R3 and R7, carried different USP6 driver mutations that may activate USP6 oncogenic function and affect the Wnt signaling individually[27] ( Figure 2E ). Meanwhile, previous studies revealed that parallel evolution might also be driven by focal amplification [9, 28] . In ICC892, the gene SMARCB1, a chromatin remodeler gene, had a trunk amplification, but they were further amplified in subclonal clusters and finally resulted in copy number hyper-diversity in the tumor sub-regions. These amplifications were validated by fluorescent in situ hybridization(FISH) analysis, using 2 probes labeling SMARCB1 (green) and 22q12 (red) respectively ( Figure 2F ).
Interestingly, the amplified alleles were always the SMARCB1-mutated Tables 6 and   7 ).
Temporal dissection of mutational spectrum and signatures
We further analyzed the mutational spectrum based on the timeline of mutation acquisition, i.e., early trunk, late trunk and non-trunk mutations. Among all mutations, C>A transversion, C>T and T>C transitions were the predominant changes, a feature shared by hepatocellular carcinoma and ICCs [29] . Similar to previous reports in ICC [5, 6] , the C>T transitions in our 6 ICCs were enriched in CpG sites, implying a common mechanism underlying ICC pathogenesis. In addition, C>A transversion increased dramatically in non-trunk mutations, while the proportion of T>C transition decreased in non-trunk ( Figure 3A and 3B).
To figure out the cause of such mutation shift, we analyzed the mutation signatures using DeconstructSigs to map the mutation to the COSMIC signatures[30] (Figure 6a ).
The signatures in the trunk and non-trunk mutation demonstrated significant differences. Correspondending to the change of C>A transversion, signature 24, observed in a subset of hepatocellular carcinoma that correlated with aflatoxin B exposure, displayed a prominent increase only in non-trunk events, especially in ICC880 and ICC1969. Additionally, the tobacco-related signature 29 was elevated in non-trunk events, consistent with the smoking history of these patients. Moreover, signature 5 was increased in 4 ICC patients, but the etiology of this signature was still unknown. These ICCs could acquire different branched driver genes with similar mutation signatures, indicating the innate essence rather than the mutation signatures may be the predominant fuel for branch process( Figure 3C ).
The distribution of signatures in the trunk was more diversified than that in the nontrunk ( Figure 3C ), implying that complicated etiology may be involved in the tumorigenesis of different individuals. Signature 1, reflecting spontaneous deamination of methylated cytosines, was identified in ICC880 and ICC1969 and was significantly more prevalent in the trunk mutation. This signature was associated with ICC patient age at diagnosis, indicating these initial mutations may accumulate with age. Another tobacco-related signature, signature 4, was found in the trunk, indicating that effect of tobacco consumption will affect the entire evolution process. Signature 16 was also found to be elevated in the trunk mutation. Signature 16 was linked with an exceptionally strong transcriptional strand bias for T>C mutations at ApTpN context but its etiology was still unknown.
The heterogeneity of CNA and chromosomal instability
We next analyzed heterogeneity at the copy number level. In contrast to high degree of ITH in somatic mutations, CNAs showed less degree of intra-tumor heterogeneity.
We detected deletions on chromosomes 1p, 4q, 7q, 8p, 13q, 16q and 22q (deletion:
<=1 copy number relative to ploidy). These deletions harbored well-known tumor suppressors, such as TP53 (17p13), RB1 (13q13) and ARID1A (1p36). ARID1A
was identified as an ICC driver in previous genomic sequencing studies [5, 6] , and its inactivation was proved to promote ICC carcinogenesis [5] . We also noted high level of amplification on chromosomes 6p, 7p, 8q, 9q and 12p, 22q (amplification: >= 2X ploidy). Known oncogenes, such as EGFR, CDK6, MET, MYC, HOXA9, and SALL4, were located in these regions ( Figure 4A ). Circos plot of 6 patients were also drawn to present the CNA profiles (Supplementary Figure 5 ). In addition, the somatic CNAs in our cohort were compared with those in another 99 ICC patients using an inhouse algorithm based on BICseq2 and GISTIC2.0 [6, 31, 32] . In total, 30 amplified segments and 20 loss segments also existed in at least one sample in our cohort, indicating a significant overlap with this dataset ( Figure 4B ). Deletions of both TP53 and ARID1A were found in half of ICCs (50/99), and high frequent amplification of the above oncogenes were also observed.
Remarkably, except for ICC1239 (diploid), the remaining 5 cases held high-ploidy karyotypes. ICC772, ICC 892, ICC1370 and ICC1969 were triploid and ICC 880 was tetraploid( Figure 4A ). The allele information of these high-ploidy tumors showed that genome doubling (GD) was shared by all regions and hence GD would be an early event in tumor progression. All the high-ploidy patients held the deletion of 17p,
where the tumor suppressor gene TP53 located. Increasingly more evidences indicted that GD events were associated with increased CIN and may forecast poor prognosis [33] . Previous study showed that a 20% threshold of the weighted Genome Instability Index (wGII) could accurately distinguish CIN+ from CIN− tumors [34] .
We found that all tumor regions in our cohort demonstrated high levels of wGII (median, 0.67; range, 0.31-0.93), indicative of CIN+. Considerably higher wGIIs were detected in high-ploid (ploidy ≥3) than diploid tumors, consistent with the results in colorectal cancer [33] ( Figure 4C ). Alternatively, studies reported that microsatellite instability existed in some ICC with a more favorable outcome and could predict the response to PD-1blockade [35, 36] . However, samples in this cohort showed very low MSI scores (Supplementary Figure 6) . These data conformed with the model that extensive CIN occurred along with the evolution and provided sufficient fuel for clonal diversification in ICC.
Timing of Clonal mutations and chromosomal alterations
Alterations in a number of driver genes were mostly truncal and occurred before GD, indicating their involvement in tumor initiation. For instance, other than SMARCB1, several other SWI/SNF complex gene, including SS18, PBRM1 and SMARCC1, also harbored clonal inactivating mutations in 4/6 cases, and most of them occurred before GD. In our 5 high-ploidy ICCs, GD was found to mainly occur later in the trunk, resulting in mutated allele copy number ≥2 for most of truncal mutations (median 83%, range, 78-89%). In other word, a significant mutational burden had already accumulated before GD in ICC.
Clonal chromosomal-arm alterations were further timed by mutated allele copy number of all genes on a given arm. In the 5 ICC, early alterations were estimated to include the amplifications of 6p, 7p and 12p and the LOH of 1p, 8p, 13q and 22q12 before GD. For example, 22q12 LOH (2+0), harboring the tumor suppressor NF2, was likely to have occurred prior to GD and promote the initiation of ICC892;
Otherwise, it would require two independent hits. The copy number of 22q12 was validated by FISH analysis in regions R3, R8 and R9( Figure 2F , the red spot).
Intrahepatic metastasis and polyclonal seeding
Next, we assessed the temporal association between the primary and recurrent lesions in ICC1239. Considering that both of them shared the same clonal mutations and similar mutation spectrum, we inferred that ICC1239R was formed by the early intrahepatic metastasis from the primary tumor ICC1239P, rather than a new multicentric tumor( Figure 5A ). If a recurrence was seeded by single tumor cell, it should carry a series of alterations that presented in all tumor cells. However, in ICC1239R, multiple mutational clusters presented subclonally in more than one recurrent region.
The recurrence would thus most likely come from multiple seeding by two or more distinct primary clusters, indicative of polyclonal metastatic seeding in ICC ( Figure   6B and 6C). The multiple seeding events could be attributed to two factors: first, a cooperative relationship existed among these clusters; second, early colonization was actively involved in remodeling local microenvironment to make it conducive to later colonization. Consistently, recent studies revealed subclonal reciprocal interaction through Wnt and Notch pathways to promote cancer metastasis [37, 38] .
Moreover, ICC1239R had an equal number of clonal mutations but much fewer subclonal mutations compared to ICC1230P ( Supplementary Figure 4 ). Many subclonal mutations in primary site, such as mutations in the genes KIAA0232 and IGF2BP3, could not be detected in the recurrence. This was consistent with the "founder effect" theory that the diversity of genome alteration in the metastases was much less than primary tumor [39, 40] ( Figure 5B and 5C ). In addition, new oncogenic events occurring during metastatic progression would endow the recurrence with a new phenotype. Although ICC were highly chemoresistant tumor, genetic alterations related to chemoresistance would make ICC1239R respond differently to chemotherapy. For example, a nonsilent mutation in PFKP (p.Ile752Leu), a gene that potentiated cancer cell survival under metabolic stress and mediated resistance to cisplatin in ovarian cancer [41] , was clonal in the region ICC1239R_R2, but undetectable in all other primary or recurrent regions. Additionally, two chemoresistance-related genes in ICC1239R_R2 exhibited copy-number loss. One was a nucleotide excision repair gene ERCC2. Its deficiency would contribute to cisplatin sensitivity in urothelial cancer and non-small cell lung cancer [42, 43] . The other was AKT-2. The loss of AKT-2 could lead to apoptosis via Bcl-2 downregulation and Bax upregulation, and sensitize cells to cisplatin [44] . Therefore, we tested the effect of cisplatin on cell viability of the primary cells derived from 1239R_R1/R2 in vitro, and the result was consistent with the genomic prediction(IC50 of R1 and R2: 11.3μmol/L and 3.5μmol/L respectively)( Figure 5D ).
These alterations thus indeed made ICC1239R_R2 more sensitive to cisplatin-based chemotherapy than other regions.
Potential target strategy for ICC treatment
We next considered all alterations with available or in-development therapeutics. To maximize tumor response, the most prior strategy was to target clonal events in all tumor cells. In 5/6 patients, there were actionable clonal truncal mutations (see Supplementary Material). TP53 in ICC1370 and ICC880, SMARCB1 and RB1 in ICC892 were clonal in all the regions, but there were no FDA-approved drugs targeting these genes. ICC1239 had a truncal IDH1 mutation (p.Arg132Cys) and a JAK1 mutation (p.Tyr1059Cys). The IDH inhibitor AG-120 and JAK inhibitor Ruxolitinib might be used for these two mutations. ICC880 had a truncal KRAS mutation (p.Gly12Asp) and the patient may benefit from Panitumumab or combinational treatment of Cetuximab plus chemotherapy [45, 46] . Except region R3, EGFR amplification were detected in all regions of ICC1969,, making them potentially sensitive to Gefitinib [47] ( Supplementary Figure 7) . We selected Gefitinib, an EGFR inhibitor, to test its effect on cell viability of PDPCs from ICC1969 using ICC772 cells without EGFR alterations as a control. The results showed that EGFR amplification indeed made ICC1969 cells more susceptible to anti-EGFR therapy ( Supplementary Figure 8) .
Considering the clonal structure in the recurrence ICC1239R, adaptive therapy, an evolution-based therapeutic strategy that aimed to prolong time to progression rather than to reduce tumor size [48] , would be optimal to control its progression.
ICC1239_R2 was sensitive to cisplatin-based chemotherapy, and thus would cost fewer intracellular resources to maintain resistance and consequently have higher fitness than resistant cells when not treated [49] ( Figure 5E ). In this model, the patient may be first given targeted trunk therapy, such as Ruxolitinib and AG-120, to dwindle the population of all clusters, followed by a non-treatment stage to allow the cell population with higher fitness (1239_R2) to expand and suppress the growth of chemo-resistant population. Next, a cisplatin-based chemotherapy in low and short burst dosage would be applied to kill most of the sensitive cells with little influence on resistant population and then be withdrawn. Gradually, the resistant population would be inhibited by the sensitive population and grow slowly and another round of targeted trunk therapy could be initiated again when the resistant population did progress. Adaptive strategies like adjusting the conduction of the drug vacations and treatments targeting different tumor branches, in conjunction with medical imaging or liquid biopsy to monitor subclonal growth ratios, could stimulate clonal competition and restrain general tumor growth [50] .
DISCUSSION
In this study, we depicted an overall picture of intratumor genetic heterogeneity and unmasked the evolutionary trajectories in ICC. Our results demonstrated that multiple evolutionary mechanisms, like branch evolution and parallel evolution of late mutations, "illusion" of clonal dominance and polyclonal metastatic seeding, had important roles in ICC progression. In addition to intrinsic genetic instability, we found that extrinsic factors, such as carcinogenic exposure, smoking history, aging and others, might collectively contribute to shape intratumor genetic heterogeneity of ICC. Notably, all the tumors in our cohort carried subclonal driver alterations, stressing the importance of spatial heterogeneity in ICC on fully capturing tumor evolutionary history and on more accurately identifying driver events as attractive therapeutic targets( Figure 6 ).
The evolution trajectory was constructed based on somatic alterations to reflect the history of ICC development, showing that branch evolution was the dominant pattern.
In fact, several targetable driver mutations, including those in JAK1, IDH1, and KRAS, were almost exclusively truncal events, which could be optional targets for devising new therapies. However, over 85% of putative driver mutations, such as ERBB2, CTNNB1, NOTH1, HIF1A, TTN, KDM3A and IKZF1 [5, 6, 51, 52] , were found to be subclonal in these 6 ICCs. Furthermore, evidence of parallel evolution of branch alterations in both SNVs and CNAs was noted, and FISH-based analyses confirmed the heterogeneity of copy-number changes. These driver alterations in parallel branches were relatively late events during tumor evolution and represented the constraints imposed on cancer development. Therefore targeting parallel evolutionary events and exploiting these cancer dependencies may be a compelling approach. In a word, we can reasonably infer that the trunk mutations in ICC may just confer fundamental ability for tumorigenesis, while the non-truncal mutations preferentially favor distinct subclonal expansions after establishment of the founding clones.
Meanwhile, our study also provided information on the divergent chromosomal instability processes related to ICC evolution and their dynamics over time. GD events, a macro-evolutionary step in cancers [33] , were observed in 5 out of 6 ICC patients. In all 5 patients, genome-doubling events were found to occur before subclonal diversification but after acquisition of most of early driver mutations, consistent with findings in colorectal and esophageal cancer that GD may accelerate cancer genome evolution [17, 33] . Furthermore, we found that all tumor regions in our cohort demonstrated high levels of chromosomal instability index, along with mutations or deletions in specific genes involved in maintaining genome integrity and DNA repair, e.g. the chromatin remodeling complex. It is worth noting that truncal mutations can be lost by later copy-number deletion, which will restrict the potential of targeted truncal strategy, especially in tumors with high chromosomal instability.
Consequently, these findings suggested that chromosomal instability was wide-spread in ICCs at both early and late stage and fueled for evolution process. As a potential therapeutic strategy, reduced genome instability may limit the ensuing heterogeneity and adaptability of cancer cells to treatments.
Interestingly, in ICC1239 with primary and intrahepatic metastatic tumors, the clear evidence of polyclonal metastatic seeding supported that tumors existed as symbiotic communities of multiple clones that were maintained during metastasis [53] . Despite intratumor heterogeneity, the truncal alterations were generally consistent between the primary and intrahepatic metastasis, indicating that multi-region sequencing of primary tumor could be adequate to find the targets in the trunk to deal with the metastasis. Meanwhile, genetic diversity of polyclonal populations could be greatly reduced in the metastasis by the "founder effect", with several newly-acquirred alterations. New alterations in 1239R_R2 made it more sensitive to the cisplatin than other recurrences, validated by in vitro drug test, which might provide a theoretical basis for adaptive therapy and showed a potential to evoke the competition between clonal subgroups in ICC.
Several limitations may undermine this study. First, although M-WES achieves more tumor diversity than single biopsy, the tissue it sampled is still limited. Hence, this approach still underestimates the number of subclones present within a given tumor, Highlights  Branch evolution is the predominant pattern in ICC, which is collectively shaped by parallel evolution and chromosome instability.
 ICC may metastasize through polyclonal seeding and the competition between subclonal population can be used to develop new treatment strategy, like adaptive therapy.
 Targeted therapy against truncal alterations, such as IDH1, JAK1, and KRAS mutations and EGFR amplification, can be a promising treatment strategy for ICC patients.
